Drugs for Opioid Use Disorder

LEARNING OBJECTIVES
Upon completion of this activity, the participant will be able to:

1. Explain the current approach to treatment of opioid use disorder.
2. Discuss the pharmacological options available for treatment of opioid use disorder and compare them based on their efficacy, safety, potential drug interactions, and availability.
3. Determine the best course of treatment for an individual patient with opioid use disorder.

DISCLOSURE
The Medical Letter requires that individuals responsible for the content on which a CME activity is based disclose to the audience when a conflict exists and when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

PRINCIPAL FACULTY FOR THIS ACTIVITY
Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.
Michael Viscusi, Pharm.D., Associate Editor has disclosed no relevant financial relationships.

ACCREDITATION
The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

The AAFP has reviewed The Medical Letter Continuing Medical Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2023 to 12/31/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This session (Issue 1684) is approved for 2 Enduring Materials, Self-Study AAFP Prescribed credits.

 This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid from 8/24/2023 to 8/24/2024. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-208964.

Successful completion of the post-test is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.

 The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This exam is acceptable for 2.0 hours of knowledge-based continuing education credit (0.2 CEU).

The American Nurses Credentialing Center (ANCC) and the American Academy of Nurse Practitioners (AANP) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

This activity, being ACCME (AMA) approved, is acceptable for Category 2-B credit by the American Osteopathic Association (AOA).

Physicians in Canada: Members of The College of Family Physicians of Canada are eligible to receive Mainpro-M1 credits (equivalent to AAFP Prescribed credits) as per our reciprocal agreement with the American Academy of Family Physicians.